TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW 31
1.4 CURRENCY AND PRICING 33
1.5 LIMITATIONS 33
1.6 MARKETS COVERED 33
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHICAL SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 DBMR TRIPOD DATA VALIDATION MODEL 39
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.6 MULTIVARIATE MODELLING 43
2.7 MARKET APPLICATION COVERAGE GRID 44
2.8 PRODUCT LIFELINE CURVE 45
2.9 DBMR MARKET POSITION GRID 46
2.10 VENDOR SHARE ANALYSIS 47
2.11 SECONDARY SOURCES 48
2.12 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PESTEL ANALYSIS 52
4.2 PORTER FIVE FORCES 53
4.3 PATENT ANALYSIS 54
4.4 PATIENT FLOW DIAGRAM 55
4.5 KEY PRICING STRATEGIES 56
4.6 FUTURE THERAPIES 57
4.7 KEY PATIENT ENROLLMENT STRATEGIES 58
5 PIPELINE ANALYSIS 59
6 EPIDEMIOLOGY 60
7 INDUSTRY INSIGHTS 61
8 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: REGULATIONS 62
9 MARKET OVERVIEW 65
9.1 DRIVERS 67
9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 67
9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 67
9.1.3 AWARENESS REGARDING THE DISEASE 68
9.2 RESTRAINTS 68
9.2.1 STRICT REGULATORY GUIDELINES 68
9.2.2 HIGH TREATMENT COSTS 68
9.3 OPPORTUNITIES 69
9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 69
9.3.2 INCREASING HEALTHCARE FACILITIES 69
9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 70
9.4 CHALLENGES 70
9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 70
9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 71
10 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 72
10.1 OVERVIEW 73
10.2 TREATMENT 76
10.2.1 MEDICATIONS, BY TYPE 76
10.2.1.1 CORTICOSTEROIDS 77
10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 77
10.2.1.2.1 AZATHIOPRINE 78
10.2.1.2.2 MYCOPHENALATE MOFETIL 78
10.2.1.2.3 METHOTREXATE 78
10.2.1.2.4 CYCLOPHOSPHAMIDE 78
10.2.1.2.5 MIZORIBINE 78
10.2.1.2.6 OTHERS 78
10.2.1.3 ANTI- INFLAMMATORY AGENTS 78
10.2.1.3.1 DIAMINODYPHENYL SULFONE 79
10.2.1.3.2 TETRACYCLINE 79
10.2.1.3.3 OTHERS 79
10.2.1.4 BIOLOGICS 79
10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 79
10.2.1.6 ANTIBIOTICS 79
10.2.1.7 ANTIFUNGALS 79
10.2.1.8 ANTIVIRALS 79
10.2.1.9 OTHER MEDICATIONS 79
10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 79
10.2.2.1 ORAL 80
10.2.2.2 TOPICAL 80
10.2.2.3 PARENTERAL 80
10.2.2.4 OTHERS 80
10.2.3 MEDICATIONS, BY DRUG TYPE 80
10.2.3.1 GENERIC 81
10.2.3.2 BRANDED 81
10.3 DIAGNOSIS 81
10.3.1 SKIN BIOPSY 82
10.3.2 BLOOD TEST 82
10.3.3 ENDOSCOPY 82
11 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 83
11.1 OVERVIEW 84
11.2 ADULTS 87
11.3 GERIATRIC 88
11.4 PEDIATRIC 89
12 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER 90
12.1 OVERVIEW 91
12.2 HOSPITALS 94
12.3 SPECIALTY CLINICS 94
12.4 RESEARCH INSTITUTES 95
12.5 OTHERS 96
13 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 97
13.1 OVERVIEW 98
13.2 HOSPITALS PHARMACY 101
13.3 RETAIL PHARMACY 101
13.4 ONLINE PHARMACY 102
14 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY REGION 103
14.1 ASIA-PACIFIC 104
14.1.1 CHINA 113
14.1.2 INDIA 117
14.1.3 SOUTH KOREA 121
14.1.4 MALAYSIA 125
14.1.5 JAPAN 129
14.1.6 AUSTRALIA 133
14.1.7 SINGAPORE 137
14.1.8 THAILAND 141
14.1.9 INDONESIA 145
14.1.10 PHILIPPINES 149
14.1.11 REST OF ASIA-PACIFIC 152
15 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 153
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 153
16 SWOT ANALYSIS 154
17 COMPANY PROFILE 155
17.1 ABBVIE INC. 155
17.1.1 COMPANY SNAPSHOT 155
17.1.2 REVENUE ANALYSIS 155
17.1.3 COMPANY SHARE ANALYSIS 156
17.1.4 PRODUCT PORTFOLIO 156
17.1.5 RECENT DEVELOPMENTS 157
17.2 MERCK & CO., INC., 158
17.2.1 COMPANY SNAPSHOT 158
17.2.2 REVENUE ANALYSIS 158
17.2.3 COMPANY SHARE ANALYSIS 159
17.2.4 PRODUCT PORTFOLIO 159
17.2.5 RECENT DEVELOPMENT 159
17.3 SANOFI 160
17.3.1 COMPANY SNAPSHOT 160
17.3.2 REVENUE ANALYSIS 160
17.3.3 COMPANY SHARE ANALYSIS 161
17.3.4 PRODUCT PORTFOLIO 161
17.3.5 RECENT DEVELOPMENT 161
17.4 REGENERON PHARMACEUTICALS INC. 162
17.4.1 COMPANY SNAPSHOT 162
17.4.2 REVENUE ANALYSIS 162
17.4.3 COMPANY SHARE ANALYSIS 163
17.4.4 PRODUCT PORTFOLIO 163
17.4.5 RECENT DEVELOPMENT 163
17.5 NOVARTIS AG 164
17.5.1 COMPANY SNAPSHOT 164
17.5.2 REVENUE ANALYSIS 164
17.5.3 COMPANY SHARE ANALYSIS 165
17.5.4 PRODUCT PORTFOLIO 165
17.5.5 RECENT DEVELOPMENT 165
17.6 AMGEN INC. 166
17.6.1 COMPANY SNAPSHOT 166
17.6.2 REVENUE ANALYSIS 166
17.6.3 PRODUCT PORTFOLIO 167
17.6.4 RECENT DEVELOPMENTS 167
17.7 ASTRAZENECA 168
17.7.1 COMPANY SNAPSHOT 168
17.7.2 REVENUE ANALYSIS 168
17.7.3 COMPANY SHARE ANALYSIS 169
17.7.4 PRODUCT PORTFOLIO 169
17.7.5 RECENT DEVELOPMENTS 170
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 171
17.8.1 COMPANY SNAPSHOT 171
17.8.2 REVENUE ANALYSIS 171
17.8.3 PRODUCT PORTFOLIO 172
17.8.4 RECENT DEVELOPMENT 172
17.9 CELLTRION HEALTHCARE CO., LTD 173
17.9.1 COMPANY SNAPSHOT 173
17.9.2 REVENUE ANALYSIS 173
17.9.3 PRODUCT PORTFOLIO 174
17.9.4 RECENT DEVELOPMENTS 174
17.10 F. HOFFMANN- LA ROCHE LTD. 175
17.10.1 COMPANY SNAPSHOT 175
17.10.2 REVENUE ANALYSIS 175
17.10.3 PRODUCT PORTFOLIO 176
17.10.4 RECENT DEVELOPMENT 176
17.11 FRESENIUS KABI AG 177
17.11.1 COMPANY SNAPSHOT 177
17.11.2 REVENUE ANALYSIS 177
17.11.3 PRODUCT PORTFOLIO 178
17.11.4 RECENT DEVELOPMENT 178
17.12 GSK PLC 179
17.12.1 COMPANY SNAPSHOT 179
17.12.2 REVENUE ANALYSIS 179
17.12.3 PRODUCT PORTFOLIO 180
17.12.4 RECENT DEVELOPMENT 180
17.13 JOHNSON & JOHNSON SERVICES, INC. 181
17.13.1 COMPANY SNAPSHOT 181
17.13.2 REVENUE ANALYSIS 181
17.13.3 COMPANY SHARE ANALYSIS 182
17.13.4 PRODUCT PORTFOLIO 182
17.13.5 RECENT DEVELOPMENT 182
17.14 LILLY 183
17.14.1 COMPANY SNAPSHOT 183
17.14.2 REVENUE ANALYSIS 183
17.14.3 PRODUCT PORTFOLIO 184
17.14.4 RECENT DEVELOPMENT 184
17.15 PFIZER INC. 185
17.15.1 COMPANY SNAPSHOT 185
17.15.2 REVENUE ANALYSIS 185
17.15.3 PRODUCT PORTFOLIO 186
17.15.4 RECENT DEVELOPMENT 186
17.16 RAKSHIT DRUGS PVT. LTD 187
17.16.1 COMPANY SNAPSHOT 187
17.16.2 PRODUCT PORTFOLIO 187
17.16.3 RECENT DEVELOPMENT 187
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 188
17.17.1 COMPANY SNAPSHOT 188
17.17.2 REVENUE ANALYSIS 188
17.17.3 PRODUCT PORTFOLIO 189
17.17.4 RECENT DEVELOPMENT 189
17.18 ZYDUS GROUP 190
17.18.1 COMPANY SNAPSHOT 190
17.18.2 REVENUE ANALYSIS 190
17.18.3 PRODUCT PORTFOLIO 191
17.18.4 RECENT DEVELOPMENT 191
18 QUESTIONNAIRE 192
19 RELATED REPORTS 194

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.